Table 3.
Univariate and multivariate analyses of factors associated with overall survival and relapse-free survival in the GSE39582 cohort.
| Univariate analysisb | Multivariate analysisb | |||
|---|---|---|---|---|
| HR (95% CI) | P valuea | HR (95% CI) | P valuea | |
| GSE39582/OS (n = 566) | ||||
| Gender (male vs. female) | 1.21 (0.986-1.486) | 0.068 | ||
| Age (≤65 vs. >65) | 0.763 (0.616-0.945) | 0.013 | 0.748 (0.602-0.93) | 0.009 |
| Stage (III-IV vs. I-II) | 1.496 (1.221-1.832) | <0.001 | 1.483 (1.205-1.825) | <0.001 |
| KRAS (wild type vs. mutant) | 0.804 (0.655-0.987) | 0.037 | 0.823 (0.67-1.011) | 0.063 |
| BRAF (wild type vs. mutant) | 0.928 (0.645-1.336) | 0.688 | ||
| TP53 (wild type vs. mutant) | 0.881 (0.688-1.127) | 0.313 | ||
| ATP8B1 expression (low vs. high) | 1.297 (1.028-1.638) | 0.028 | 1.207 (0.953-1.53) | 0.119 |
| GSE39582/RFS (n = 566) | ||||
| Gender (male vs. female) | 1.182 (0.956-1.463) | 0.123 | ||
| Age (≤65 vs. >65) | 1.117 (0.905-1.379) | 0.301 | ||
| Stage (III-IV vs. I-II) | 2.067 (1.658-2.577) | <0.001 | 1.934 (1.546-2.421) | <0.001 |
| KRAS (wild type vs. mutant) | 0.781 (0.63-0.967) | 0.023 | 0.814 (0.657-1.008) | 0.06 |
| BRAF (wild type vs. mutant) | 1.051 (0.703-1.572) | 0.809 | ||
| TP53 (wild type vs. mutant) | 0.804 (0.627-1.031) | 0.085 | ||
| ATP8B1 expression (low vs. high) | 1.541 (1.153-2.059) | 0.003 | 1.464 (1.089-1.969) | 0.012 |
aCohorts were calculated using the Cox proportional hazards regression model. Bold indicates statistically significant values. bMultivariate analysis used the covariates associated with survival in the univariate models (P < 0.05). The Wald statistic was applied to test whether the covariates were independent variables (P < 0.05). Bold indicates statistically significant values.